New treatments to enhance or restore how cells produce energy

View our Pipeline

At Imbria, our mission is to translate our understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options.

Developing new treatments for cardiometabolic disorders

Non-obstructive hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with a prevalence in the general population of 1:200.

Stable angina

Chest pain from angina can feel like a heart attack. Stable angina affects more than 4% of the adult population and leads to significant reduction in quality of life.

Heart failure with preserved ejection fraction

Heart failure is a clinical syndrome characterized by the inability of the heart to sufficiently pump blood to meet the body’s metabolic needs.

Pipeline & Technology

Advancing novel product candidates for cardiac disease

Read more

Patients & Physicians

Turning our knowledge of cellular metabolism into new medicines that improve the lives of patients

Read more

Latest news

Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction

Read more
December 05, 2022

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

December 05, 2022

Ninerafaxstat to Provide Optimal Ventricular Energetics in HCM: IMPROVE-HCM

October 10, 2022

Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase

September 15, 2022

Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium

View all news

You Are About to Leave Imbria Pharmaceuticals

The appearance of external hyperlinks does not constitute endorsement by Imbria Pharmaceuticals of the linked websites, or the information, products or services contained therein.

Back Continue